HalioDx Overview

  • Founded
  • 2014

  • Status
  • Acquired/​Merged

  • Employees
  • 240

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $320M

HalioDx General Information


Developer of a line of immunologic scoring tests intended to investigate the immune response within the tumor environment. The company's tests are developed using a proprietary set of Immune biomarkers, advanced image analysis technologies to precisely measure the immune reaction in and around the tumor, enabling clinicians to determine the degree of severity of the patient's disease and to predict response to treatment.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Parent Company
Primary Office
  • Luminy Biotech Entreprises
  • 163 Avenue de Luminy, Marseille Cedex 9
  • 13288 Marseille
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HalioDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 02-Aug-2021 $320M 0000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 10-Dec-2018 0000 0000 000.00 Completed Generating Revenue
2. Buyout/LBO (MBO) 15-Jun-2015 $9.5M 000.00 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view HalioDx’s complete valuation and funding history, request access »

HalioDx Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ABSA 00,000 0000.00 0000.00 00 0000.00 00.000
ADP B 00,000 0000.00 0000.00 00 0000.00 00.000
To view HalioDx’s complete cap table history, request access »

HalioDx Patents

HalioDx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160076089-A1 A method for dna amplification with a blocking oligonucleotide Granted 29-Apr-2013 0000000000
US-10760118-B2 Method for dna amplification with a blocking oligonucleotide Active 29-Apr-2013 0000000000 0
JP-6652693-B2 Method of dna amplification using blocking oligonucleotide Active 29-Apr-2013 0000000000
JP-2016516432-A Dna amplification method using blocking oligonucleotide Granted 29-Apr-2013 0000000000
JP-2019004914-A Methods for amplifying dna using blocking oligonucleotides Withdrawn 29-Apr-2013 C12Q1/6858
To view HalioDx’s complete patent history, request access »

HalioDx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HalioDx Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amundi Private Equity Funds PE/Buyout Minority 000 0000 000000 0
BNP Paribas Asset Management Asset Manager Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Capricorn Partners Venture Capital Minority 000 0000 000000 0
Grand Luminy Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »